Luo S, Peng H, Shi Y, Cai J, Zhang S, Shao N
Brief Bioinform. 2025; 26(2).
PMID: 40052441
PMC: 11886573.
DOI: 10.1093/bib/bbaf087.
Jiang L, Baker S, Ceccarelil M, Guo Y
HLA. 2025; 105(2):e70049.
PMID: 39957309
PMC: 11839181.
DOI: 10.1111/tan.70049.
Ying H, Wu X, Jia X, Yang Q, Liu H, Zhao H
EBioMedicine. 2025; 113:105596.
PMID: 39933264
PMC: 11867302.
DOI: 10.1016/j.ebiom.2025.105596.
Lopez M, Spehner L, Andre F, Viot J, Seffar E, Marguier A
Breast Cancer Res. 2025; 27(1):19.
PMID: 39920833
PMC: 11806781.
DOI: 10.1186/s13058-025-01962-6.
Wu J, Liu N, Chen J, Tao Q, Lu C, Li Q
J Immunother Cancer. 2025; 13(2).
PMID: 39915005
PMC: 11804206.
DOI: 10.1136/jitc-2024-010252.
Evolutionary trajectories of immune escape across cancers.
Chen W, Baker T, Zhang Z, Ogilvie H, Van Loo P, Gu S
bioRxiv. 2025; .
PMID: 39868264
PMC: 11761017.
DOI: 10.1101/2025.01.17.632799.
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Jammihal T, Saliby R, Labaki C, Soulati H, Gallegos J, Peris A
Nat Cancer. 2025; 6(2):372-384.
PMID: 39789182
DOI: 10.1038/s43018-024-00896-w.
Comprehensive genomic characterization of early-stage bladder cancer.
Prip F, Lamy P, Lindskrog S, Strandgaard T, Nordentoft I, Birkenkamp-Demtroder K
Nat Genet. 2025; 57(1):115-125.
PMID: 39753772
PMC: 11735393.
DOI: 10.1038/s41588-024-02030-z.
Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer.
Qiao Y, Hui K, Hu C, Wang M, Sun W, Liu L
Cancer Immunol Immunother. 2025; 74(2):60.
PMID: 39751937
PMC: 11699067.
DOI: 10.1007/s00262-024-03906-z.
Cancer immune evasion, immunoediting and intratumour heterogeneity.
Roerden M, Spranger S
Nat Rev Immunol. 2025; .
PMID: 39748116
DOI: 10.1038/s41577-024-01111-8.
Immunogenic peptides putatively from intratumor microbes: Opportunities for colorectal cancer treatment.
Guan X, Bu F, Fu Y, Zhang H, Xiang H, Chen X
iScience. 2024; 27(12):111338.
PMID: 39640572
PMC: 11617993.
DOI: 10.1016/j.isci.2024.111338.
Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies.
Gormally M, Chen M, Noronha A, Panageas K, Reynolds M, Kohlasch K
JAMA Oncol. 2024; 11(1):74-76.
PMID: 39602136
PMC: 11603376.
DOI: 10.1001/jamaoncol.2024.5364.
Landscape of targeted therapies for lung squamous cell carcinoma.
Chen Q, Zheng X, Cheng W, Li J
Front Oncol. 2024; 14:1467898.
PMID: 39544292
PMC: 11560903.
DOI: 10.3389/fonc.2024.1467898.
Best practices for germline variant and DNA methylation analysis of second- and third-generation sequencing data.
Bonfiglio F, Legati A, Lasorsa V, Palombo F, De Riso G, Isidori F
Hum Genomics. 2024; 18(1):120.
PMID: 39501379
PMC: 11536923.
DOI: 10.1186/s40246-024-00684-8.
Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project.
Ni Leathlobhair M, Frangou A, Kinnersley B, Cornish A, Chubb D, Lakatos E
Nat Commun. 2024; 15(1):9247.
PMID: 39461959
PMC: 11513037.
DOI: 10.1038/s41467-024-53193-6.
Harnessing the power of AI in precision medicine: NGS-based therapeutic insights for colorectal cancer cohort.
Pienkowski V, Skoczylas P, Zaremba A, Klek S, Balawejder M, Biernat P
Front Oncol. 2024; 14:1407465.
PMID: 39435285
PMC: 11491396.
DOI: 10.3389/fonc.2024.1407465.
Genetic alteration of class I HLA in cutaneous T-cell lymphoma.
Kwang A, Duran G, Fernandez-Pol S, Najidh S, Li S, Bastidas Torres A
Blood. 2024; 145(3):311-324.
PMID: 39388712
PMC: 11775508.
DOI: 10.1182/blood.2024024817.
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.
Puttick C, Jones T, Leung M, Galvez-Cancino F, Liu J, Varas-Godoy M
Nat Genet. 2024; 56(10):2121-2131.
PMID: 39358601
PMC: 11525181.
DOI: 10.1038/s41588-024-01883-8.
Variation within the non-coding genome influences genetic and epigenetic regulation of the human leukocyte antigen genes.
Arumugam T, Adimulam T, Gokul A, Ramsuran V
Front Immunol. 2024; 15:1422834.
PMID: 39355248
PMC: 11442197.
DOI: 10.3389/fimmu.2024.1422834.
Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes.
Tokita S, Fusagawa M, Matsumoto S, Mariya T, Umemoto M, Hirohashi Y
Sci Adv. 2024; 10(38):eado6491.
PMID: 39292790
PMC: 11409964.
DOI: 10.1126/sciadv.ado6491.